Keyword: Brigham and Women's Hospital
Modifying tumor cells instead of immune cells from patients is showing promising results in animal models of breast and brain cancer.
Last week’s biotech discoveries include a gut-coating pill that lowers glucose and prostate-tumor test to predict a good response to immunotherapy.
A PureTech startup is developing an immune-responsive hydrogel that releases a corticosteroid into arthritic joints based on their level of inflammation.
The hospital network achieved the jump in scale by turning to outside backers including Eli Lilly, which collectively pumped $66 million into the fund.
Neuroscientists at Brigham and Women's Hospital were searching for clues to the development of MS when they found an antibody with cancer-fighting properties.
Researchers have highlighted a novel pathway in which a specific microRNA (also known as miRNA) can help to positively regulate arterial thrombosis.
Once again scientists are looking to the gut to find therapeutic pathways that lead to the rest of the body.
Administering mesenchymal stem cells with drug-laden microparticles may hold promise in targeting prostate cancer while leaving neighboring cells unscathed.